Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations

Table 1 Telomerase reverse transcriptase promoter mutations in hepatocellular carcinoma cell lines

Cell lines	TERT promoter status
Epitheliel-like
Huh7	C228T
HepG2	C228T
Hep3B	C228T
FLC4	C228T
Hep40	Wild-type
PLC/PRF/5	Wild-type
Mesenchymal-like
FOCUS	C228T
SNU387	C228T
SNU398	C228T
SNU423	C228T
SNU475	C228T
Mahlavu	C250T
SNU182	Wild-type
SNU449	Wild-type
SKHEP1	Wild-type

TERT: Telomerase reverse transcriptase promoter.

Table 2 Telomerase reverse transcriptase promoter mutation analysis of hepatocellular carcinoma tumors

Country	TERT mutations		p53 mutations		MDM2	HBV	Stage
	C228T	C250T	Codon	Amino Acid change	SNP 309
Japan	C228T	WT	6 bp del	Del (AGCTAC)	G/G	Minus1	Unknown
Japan	C228T	WT		WT	T/G	Minus1	Unknown
Japan	C228T	WT		WT	T/G	Minus1	Unknown
Japan	WT	C250T		WT	G/G	Minus1	Unknown
Japan	WT	WT		WT	T/G	Minus1	Unknown
Japan	WT	WT		WT	T/G	Minus1	Unknown
Japan	WT	WT		WT	T/G	Minus1	Unknown
Japan	WT	WT		WT	T/G	Minus1	Unknown
Japan	WT	WT		WT	T/G	plus1	Unknown
Japan	WT	WT		WT	G/G	Minus1	Unknown
Japan	WT	WT		WT	T/G	Minus1	Unknown
China	WT	WT	281	C > A Asp > Glu	T/T	plus1	Unknown
China	WT	WT		WT	G/G	Plus1	Unknown
China	WT	WT		WT	T/G	Plus1	Unknown
China	WT	WT		WT	T/T	Plus1	Unknown
China	WT	WT		WT	G/G	Plus1	Unknown
China	WT	WT		WT	T/T	Plus1	Unknown
China	WT	WT		WT	G/G	Plus2	Unknown
China	WT	WT		WT	G/G	plus1	Unknown
Israel	WT	WT		WT	T/G	Minus1	Unknown
Mozambique	C228T	WT	157	G > T Val > Phe	T/T	Plus1	Late
Mozambique	C228T	WT		WT	T/T	Plus2	Late
Mozambique	WT	C250T		WT	T/T	Plus2	Late
Mozambique	WT	C250T	249	G > T Arg > Ser	T/T	Minus1	Early
Mozambique	WT	WT		WT	T/T	Plus2	Late
Mozambique	WT	WT	249	G > T Arg > Ser	T/T	Plus1	Late
Transkei	C228T	WT		WT	T/T	NT	Late
Transkei	C228T	WT		WT	T/T	NT	Late
Transkei	WT	WT		WT	T/T	NT	Early
Transkei	WT	WT		WT	T/T	Plus1	Late
Lesotho	WT	C250T		WT	T/T	Plus2	Early
Lesotho	WT	WT		WT	T/G	Plus2	late
Swaziland	WT	WT		WT	T/T	Plus	Early
South Africa	C228T	WT		WT	T/T	Plus2	Late
South Africa	WT	WT		WT	T/G	Plus2	Late
Germany	C228T	WT		WT	G/G	Minus1	Metastasis
Germany	C228T	WT	273	C > T Arg > Cys	T/T	Minus1	HCC
Germany	WT	C250T		WT	G/G	Plus2	HCC
Germany	WT	WT		WT	G/G	Minus1	Unknown
Germany	WT	WT		WT	G/G	Minus1	Metastasis
Germany	WT	WT		WT	T/T	Plus2	Unknown
Germany	WT	WT		WT	T/G	Plus2	HCC
France	WT	WT		WT	T/G	Minus1	Unknown
France	WT	WT		WT	T/G	Minus1	Unknown

¹means reference 17;

²means reference 18. The collection of tumor samples used for telomerase reverse transcriptase (TERT) promoter mutation analysis is displayed together with complementary data. WT: Wild type; Del: Deletion; HCC: Hepatocellular carcinoma; SNP: Single nucleotide polymorphism; MDM2: Murine double minute 2; HBV: Hepatitis B viral.

Table 3 Characteristics of the patients according to telomerase reverse transcriptase promoter mutation status n (%)

Variable	Overall series	TERT promoter mutated	TERT promoter non-mutated	P value
	(n = 44)	(n = 15)	(n = 29)
Gender
Male	27	10	17	0.2059
Female	1	1	0
Age
≥ 60 yr	9	3 (33)	6 (67)	0.6547
< 60 yr	19	8 (42)	11 (58)
Geographical origin
African	15	8 (53)	7 (47)	0.0528
Non-African	29	7 (24)	22 (76)
HBV DNA
Positive	23	6 (26)	17 (74)	0.2950
Negative	18	7 (39)	11 (61)
TP53
Mutated	6	3 (50)	3 (50)	0.6315
Wild-type	38	11 (29)	27 (71)
MDM2 SNP 309
TT	18	8 (44)	10 (56)
TG	15	2 (13)	13 (87)	0.0528 (vs TT)
GG	11	4 (36)	7 (64)

TERT: Telomerase reverse transcriptase; SNP: Single nucleotide polymorphism; MDM2: Murine double minute 2; HBV: Hepatitis B viral.